Q. This is ACROBiosystems’ first time as a sponsor for BIX. Could you tell us about ACROBiosystems and its role in the bio-pharmaceutical industry? 

A. ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.

Q. Please tell me what visitors should pay attention to when they visit ACROBiosystems’ booth or what key products or technologies do you want to show? 

A. When visiting our booth, you may notice that we always mention emphasize solutions rather than products – and this reflects our way of addressing challenges. We offer a comprehensive array of tools and reagents designed for each development phase. Starting from discovery and development and moving beyond commercialization, we strive to deliver high quality solutions that support each step of the development process. This means bringing together innovation and technology through product development and collaborations to help our customers achieve results that are translatable into the clinic and beyond. When it comes to specific products, I encourage all of you to ask about our antibody-drug conjugate solutions and especially our new conjugation kit. We have also launched new organoid-based solutions as well as GMP-grade reagents to assist with cell therapy manufacturing from pilot to the clinic.

Q. Could you give us a snapshot of the topic that ACROBiosystems will be presenting to the audience? What are the key points of the session?  

A. The topic that we’ll be presenting is the current state of antibody-drug conjugates and its challenges that are currently faced in the industry from a supplier’s perspective. Despite its background as a combination of two very mature modalities, ADCs are a manufacturing challenge. The intersection of small chemical molecules with targeting macromolecules means that the techniques not only for manufacturing but also validation needs to incorporate what’s commonly done in biology as well as chemistry. Within the talk, we’ll dive more in-depth about the key challenges we see commonly see our customers facing and some of key solutions that we offer alongside with techniques to validate our solutions that can help accelerate the development of ADCs. 

Q. How would you explain ACROBiosystems at BIX2024 in a few sentences? 

A. I would explain ACROBiosystems as a ‘Partner-of-Choice’ as a solution provider. With an expansive catalog, we offer a wide array of solutions that are designed, optimized, and validated for select applications within a specific modality. Of course, we also offer custom development and analytical services, all of which can be tailored. As such, ACROBiosystems is a supplier that delivers high-quality solutions that supports each step of the development process, from discovery to the clinic.